FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments

The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.